Holen Sie sich die Stockscreener-App
104.49
0.60%
0.62
Handel nachbörslich:
104.49
Schlusskurs vom Vortag:
$103.87
Offen:
$103.84
24-Stunden-Volumen:
609.89K
Relative Volume:
0.64
Marktkapitalisierung:
$5.71B
Einnahmen:
$1.34M
Nettoeinkommen (Verlust:
$-173.66M
KGV:
-25.25
EPS:
-4.1385
Netto-Cashflow:
$-130.49M
1W Leistung:
+3.46%
1M Leistung:
+9.59%
6M Leistung:
+107.69%
1J Leistung:
+386.00%
1-Tages-Spanne:
$103.29
$107.03
1-Wochen-Bereich:
$100.11
$107.03
52-Wochen-Spanne:
$18.08
$107.99
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
104.49 | 5.68B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Dianthus Therapeutics, Inc. $DNTH Shares Bought by SummitTX Capital L.P. - MarketBeat
Octagon Capital Advisors LP Has $163.36 Million Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics Inc (DNTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dianthus Therapeutics Inc (DNTH) Cash Flow - TradingKey
Dianthus Therapeutics Inc (DNTH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dianthus Therapeutics, Inc. Revenue Breakdown – NASDAQ:DNTH - TradingView
Dianthus Therapeutics, Inc. Revenue Breakdown – BOATS:DNTH - TradingView
Spruce Street Capital LP Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
DNTH|Dianthus Therapeutics Inc|Price:103.870|Chg%:-0.920 - TradingKey
Walleye Capital LLC Has $12.89 Million Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Jennison Associates LLC Buys New Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineProfit Announcement - dars.gov.et
Wedbush Maintains Dianthus Therapeutics (DNTH) Outperform Recommendation - MSN
Dianthus Therapeutics Stock Surges After Initiating Major Phase 3 Clinical Trial - TIKR.com
Enterprise value to EBITDA forward of Dianthus Therapeutics, Inc. – FWB:87E - TradingView
Dianthus Therapeutics, Inc. (DNTH) reports Q1 loss, lags revenue estimates - MSN
Dianthus Therapeutics DNTH Jumps As Phase 3 EMERGE Trial Kicks Off - timothysykes.com
DNTH Stock Pops As Phase 3 EMERGE Trial Kicks Off - StocksToTrade
Dianthus Therapeutics stock hits 52-week high at 102.38 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 102.38 USD - Investing.com India
Dianthus Therapeutics Rockets As Phase 3 Hype Builds - TipRanks
Form 4 Dianthus Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Dianthus therapeutics CFO Ryan Savitz sells $3.16 million in shares By Investing.com - Investing.com Australia
Dianthus therapeutics CFO Ryan Savitz sells $3.16 million in shares - Investing.com
Dianthus Therapeutics (DNTH) CFO sells 31,249 shares in 10b5-1 trades - Stock Titan
Dianthus Therapeutics (DNTH) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentMid-Term Outlook - Bölüm Sonu Canavarı
Dianthus Therapeutics (DNTH) Starts Phase 3 EMERGE Trial, Is The Upside Already Priced In? - Sahm
Form 144 Dianthus Therapeutics For: 9 July By Investing.com - Investing.com South Africa
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan
Dianthus Therapeutics stock hits 52-week high at 99.36 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 99.36 USD - Investing.com
Dianthus Advances Claseprubart Into Phase 3 EMERGE Trial, Raising Stakes in the Myasthenia Gravis Market - TipRanks
Price to earnings forward of Dianthus Therapeutics, Inc. – MUN:87E - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Enterprise value to revenue forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
DNTHDianthus Therapeutics Inc Revenue Breakdown - Finviz
Dianthus Therapeutics Inc. Q1 2026 Earnings: EPS Surprise of 22.28% Drives Positive Stock ReactionRevenue Per Share - dars.gov.et
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
DNTH News | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
Cartesian Therapeutics Announces New Employment Inducement Grants - Yahoo Finance
Price to book forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits
Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial - Sahm
Dianthus Therapeutics stock hits 52-week high at 96.85 USD By Investing.com - Investing.com South Africa
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2000 Value Benchmark - marketscreener.com
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):